Repligen extends Protein A ligand supply deal with GE Healthcare

By Dan Stanton

- Last updated on GMT

Protein A OK! Image: iStock/oanav
Protein A OK! Image: iStock/oanav

Related tags Protein

Protein A is essential in keeping the costs and complexity of purifying monoclonal antibodies down, says GE Healthcare as it extends its supply agreement with Repligen.

Massachusetts-based life sciences company Repligen manufactures Protein A ligands, a critical component of Protein A chromatography media, from its facilities in Lund, Sweden, and Waltham, Massachusetts.

The firm has been supplying bioprocessing tech firm GE Healthcare for over 15 years, but announced this week it has struck a deal to extend supply through to 2019 from the Swedish facility and 2021 from the US site.

“Repligen is one of the largest producers of Protein A ligands and GE has a long standing Strategic Supplier Alliance Agreement with them,” GE’s BioProcess Senior Product Manager Jonathan Royce told

They have an excellent track record of supplying us with Protein A ligands and have been recognized on several occasions as a top supplier to GE Healthcare.”

He added Repligen’s two separate manufacturing sites was also a key in the supply extension as it “aligns directly with GE’s overall Security of Supply program which ensures an uninterrupted supply of critical raw materials to our customers.”

Protein A

Despite the cost of Protein A, the efficacy of the resin in capturing antibodies in the downstream process is undeniable, and ensuring supply is essential as the biopharma world continues to focus on mAbs and Fc-fusion proteins, Royce continued.

“Protein A provides unmatched purity in a single purification step and allows companies to build purification platforms which simplify manufacturing and process development operations.

“Without Protein A, the purification of monoclonal antibodies would be far more complex and expensive than it is today.”

GE couples the ligands to its own agarose-based chromatography beads, and performs QC analysis and final filling of these products at its site in Uppsala, Sweden.

According to Royce, the Uppsala site is one of the largest in the world for the production of chromatography media, producing over 350,000 liters per year for its biopharma customers.

Related news

Show more

Related products

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us


View more